Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial) - Wikidata - awgldk - TriplyDB

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)

http://www.wikidata.org/entity/Q35114865

about

The 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic Infections Modeling transportation of efavirenz: inference on possibility of mixed modes of transportation and kinetic solubility.Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.

P2860

Q26751038-6D4C2423-7C0D-4705-9205-FF5683A88921 Q35691622-3EC024BD-B493-4679-B5C9-742E912BDE84 Q38755666-DB5BB2C9-7D2E-41A1-9310-02E7BF7BDCD5 Q40694902-2112B81A-CDD7-4DA2-8F8A-BFDC6F7EEAD4 Q41333285-293BE0F6-9421-4DF6-83C6-6AF4B96964F0 Q46460183-4D6EBB70-CE73-4CCE-A299-8893AD16AC60 Q52330065-F3FC95FB-F1B9-453C-AF1E-66BADF624B70

P2860

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)

http://www.wikidata.org/entity/Q35114865

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Plasma concentrations, efficac ...... 295-CIPRA KH001 CAMELIA trial)

@ast

Plasma concentrations, efficac ...... 295-CIPRA KH001 CAMELIA trial)

@en

type

label

Plasma concentrations, efficac ...... 295-CIPRA KH001 CAMELIA trial)

@ast

Plasma concentrations, efficac ...... 295-CIPRA KH001 CAMELIA trial)

@en

prefLabel

Plasma concentrations, efficac ...... 295-CIPRA KH001 CAMELIA trial)

@ast

Plasma concentrations, efficac ...... 295-CIPRA KH001 CAMELIA trial)

@en

P1433

Q35114865-52C2F26F-C4F6-408A-B2AD-98CCB107458D

P1476

Q35114865-3859261F-6255-4168-AE28-C09C7C4482D8

P2093

Q35114865-08E3C246-7F2E-48FB-846F-DC30C32F089E

Q35114865-08E3F5A0-FA75-4567-8F60-8098948EB58B

Q35114865-2AF65C70-E751-44F9-98CD-31704C1EC704

Q35114865-32790E2A-8579-46F8-9F1B-F7641AE980FF

Q35114865-4FE4A6D1-6822-4F19-B917-66C81B6B9FD6

Q35114865-531AC1BF-24D4-4B0C-88AD-0014F78821B7

Q35114865-9134BD95-C9C7-4B1E-BA1D-C5FB712ED96B

Q35114865-AD5A1F33-2C2F-4382-8CDE-83820397C01B

Q35114865-B3A7ACA9-54F2-484A-80EF-66F78F2DA8F5

Q35114865-B9689784-423F-40A8-8519-18330166ECC6

P2860

Q35114865-0038B2EC-5055-4703-83E7-8ED620D313A6

Q35114865-0A926BAE-D04A-4753-8285-9FBA21FB1D46

Q35114865-0CE834E6-3EFA-4D98-888A-3E5DD20B9BA2

Q35114865-168F823C-D140-42AA-9FD3-B28118454910

Q35114865-1D53E5B5-F2D4-47FA-AB56-0B23FAA96B74

Q35114865-1EAA3450-FD7E-40FF-8CAB-F2322FD12670

Q35114865-24315F86-B6EC-4B2D-A898-F1A263CFE760

Q35114865-2B6E433C-78B1-4BE8-A552-5E479D0252C3

Q35114865-30CD33D8-E384-43BC-92F1-E411D6935D7B

Q35114865-3B97FB35-102C-4B92-A117-EB068A1EAF39

P304

Q35114865-650A631E-DD68-4C49-9B70-50E8F63E6ADC

P31

Q35114865-AF55F057-0D9C-417B-9FF8-80F4804F70CD

P356

Q35114865-03FB8E2C-A106-4D2B-991C-521D6271B772

P407

Q35114865-6B976C23-6306-4209-9E49-19D818BEBB14

P433

Q35114865-F1379E60-D46B-4E67-915C-07AE9B456F94

P478

Q35114865-D8C756CD-6E35-49F8-BCDD-65979A80A5A7

P50

Q35114865-0A06CF65-5007-44E5-AEA8-44C077BC3122

Q35114865-119A3A27-85A7-4821-9928-066955045017

Q35114865-A2C9CA2F-50DD-4980-9C10-7817795DE55C

Q35114865-DDBF16B8-5360-484D-9411-7451F6197410

P577

Q35114865-96F9A1DE-3A1C-42E5-8F9C-7DF5962B3AE3

P5875

Q35114865-C42FE232-5913-4E2A-A08D-1D022991F5E7

P698

Q35114865-D932B394-E3A9-479A-9998-A81C55EB2BDC

P921

Q35114865-3B86E099-A47D-4C33-A67A-257C50786BA6

Q35114865-93D2FFE9-C3A3-4CCA-83F1-C4E993E06816

P932

Q35114865-A4DE0547-BCE5-471C-A67A-311104C9D3C6

P356

JOURNAL.PONE.0090350

P1433

P1476

Plasma concentrations, efficac ...... 295-CIPRA KH001 CAMELIA trial)

@en

P2093

Anne E Goldfeld

http://www.w3.org/2001/XMLSchema#string

Anne-Marie Taburet

http://www.w3.org/2001/XMLSchema#string

Bunnet Dim

http://www.w3.org/2001/XMLSchema#string

Chanroeun Hak

http://www.w3.org/2001/XMLSchema#string

Chindamony Kim

http://www.w3.org/2001/XMLSchema#string

Didier Laureillard

http://www.w3.org/2001/XMLSchema#string

Khemarin Kim Lak

http://www.w3.org/2001/XMLSchema#string

Laurence Borand

http://www.w3.org/2001/XMLSchema#string

Monidarin Chou

http://www.w3.org/2001/XMLSchema#string

Narom Prak

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers

Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

P304

e90350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0090350

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Arnaud Fontanet

François-Xavier Blanc

P577

2014-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260646023

http://www.w3.org/2001/XMLSchema#string

P698

24608960

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3946522

http://www.w3.org/2001/XMLSchema#string